Bill joined Blue Fin Group from McKesson Specialty, where he most recently led several of their Specialty assets and a large team of associates. He brings deep cross-functional experience that will benefit Blue Fin Group clients tremendously from the perspective of product strategy, policy and reimbursement, payer strategy and market access, patient access and affordability, provider, pharmacy, distribution and logistics.
From his start in nursing home administration, to his roles with Aetna, Merck and McKesson, Bill has always been on the forefront of the industry and stamps his work with the mark of vision and excellence. He has worked with most of the nation’s pharmaceutical and biotech manufacturers; focused on enabling their commitment to aiding patients across many aspects of their healthcare journey.
Bill envisions a world of Cell and Gene and Orphan Rare therapies that will require different commercial thinking and execution than has been seen before. He is driven to create long-term sustainable solutions for our clients, and he shares our collective passion for Blue Fin Group’s mission, which is to connect science with affordable access for patients.